Accuracy and utility of blood and urine biomarkers for the noninvasive diagnosis of endometriosis: a systematic literature review and meta-analysis

Dolińska, Wioletta; Draper, Hannah; Othman, Lara; Thompson, Chloe; Girvan, Samantha; Cunningham, Keith; Allen, Jane; Rigby, Alan S.; Phillips, Kevin; Guinn, Barbara

doi:10.1016/j.xfnr.2022.12.001

Cited by 8 publications

(7 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite numerous studies aiming to identify non-invasive biomarkers for this condition, challenges persist due to variabilities in study design, a lack of consensus on the disease's pathophysiology, and the absence of specific symptoms, leading to delayed diagnosis. The gold standard for diagnosing endometriosis remains invasive surgery followed by histopathological examination, underscoring the urgent need for more reliable and standardized non-invasive biomarkers [ 12 , 13 , 34 ]. The research underscores the importance of developing biomarker panels rather than relying on single biomolecules for diagnosing endometriosis.…”

Section: Reviewmentioning

confidence: 99%

A Comprehensive Review of the Diagnostic Landscape of Endometriosis: Assessing Tools, Uncovering Strengths, and Acknowledging Limitations

Dantkale,

Agrawal

2024

Cureus

View full text Add to dashboard Cite

Endometriosis is a prevalent yet often underdiagnosed condition characterized by the presence of endometrial-like tissue outside the uterus, leading to significant morbidity and impaired quality of life. A timely and accurate diagnosis of endometriosis is essential for effective management and improved patient outcomes. This review provides a comprehensive overview of the current diagnostic landscape of endometriosis, including clinical evaluation, imaging modalities, biomarkers, and laparoscopy. The strengths and limitations of each diagnostic approach are critically evaluated, alongside challenges such as delayed diagnosis and misinterpretation of findings. The review emphasizes the importance of multidisciplinary collaboration, standardized diagnostic protocols, and ongoing research to enhance diagnostic accuracy and facilitate early intervention. By addressing these challenges and leveraging emerging technologies, healthcare professionals can improve the diagnosis and management of endometriosis, ultimately enhancing the well-being of affected individuals.

show abstract

Section: Reviewmentioning

confidence: 99%

A Comprehensive Review of the Diagnostic Landscape of Endometriosis: Assessing Tools, Uncovering Strengths, and Acknowledging Limitations

Dantkale,

Agrawal

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…На сьогодні вченими ендометріоз розглядається як хронічне запальне захворювання, що визначається як наявність ендометрійподібної тканини поза маткою. Утворення та ріст такої ендометріоїдної тканини є естрогензалежними, тому це здебільшого спостерігається у жінок репродуктивного віку, хоча клінічні наслідки ендометріозу та його лікування можуть тривати навіть після настання менопаузи [1,5].…”

Section: г і н е к о л о г і яunclassified

“…Доведено, що ендометріоз може виснажувати жінку фізично та емоційно, тим самим значно знижуючи якість її життя [8]. І хоча не всі жінки з ендометріозом мають симптоми: біль, пов'язаний з ендометріозом, або безпліддя, що є клінічною ознакою захворювання, він уражує не лише жінок з ендометріозом, а й їхніх партнерів у сім'ї [5,9]. Було встановлено, що ендометріоз, зокрема больові симптоми, впливають на якість життя, на низку видів діяльності та життєвих сфер, включаючи фізичне функціонування, повсякденну діяльність і соціальне життя, освіту та роботу, секс, інтимні відносини та інтимне партнерство, а також психічне здоров'я та емоційне благополуччя.…”

Section: г і н е к о л о г і яunclassified

“…Незважаючи на все, наведене вище, на сьогодні все ще існує великий діагностичний проміжок між появою симптомів і встановленням правильного діагнозу у середньому від 8 до 12 років [5]. Терапевтичні варіанти варіюються від зменшення симптомів болю та покращення перспектив фертильності за допомогою гормонального зниження рівня ендогенного естрогену, проапоптозної та протизапальної дії на ендометріоїдну тканину, хірургічного видалення або деструкції ендометріоїдних уражень і розділення спайок до лікування хронічних больових синдромів.…”

Section: г і н е к о л о г і яunclassified

See 1 more Smart Citation

The role of progestogens in the treatment of endometriosis

Zhylka,

Shcherbinska

2023

RHW

View full text Add to dashboard Cite

According to global data the prevalence of endometriosis ranges from 2 to 10% among the general female population and up to 50% among women with infertility. Therefore, at least 190 million women and adolescent girls worldwide have been diagnosed with this disease.Endometriosis, according to evidence, can exhaust a woman physically and emotionally, thereby significantly reducing her quality of life. In particular, pain symptoms affect quality of life and a range of activities and life domains, including physical functioning, daily activities and social life, education and work, sex, intimate relationships and intimate partnerships, and mental health and emotional well-being.This pathology is often accompanied by infertility. Endometriosis has social importance in general, for example due to direct and indirect health care costs comparable to other common diseases such as type 2 diabetes, rheumatoid arthritis and Crohn’s disease.The pathogenesis of endometriosis prompts scientists to search for new methods of conservative treatment. One of the modern means that allow to expand the clinical possibilities of impact on endometriosis is a drug from the dienogest group. The commitment of specialists to the use of dienogest is significantly influenced by the understanding of its pharmacokinetics. After oral use, dienogest is quickly and completely absorbed. The maximum concentration in blood serum is reached within 1.5 hours after a single oral intake and is 47 ng/ml.The bioavailability of dienogest is quite high and is approximately 91%. Its pharmacokinetics are dose-dependent in the dose range of 1–8 mg. Dienogest at a dose of 2 mg/day is an effective alternative to surgery for the long-term treatment of endometriosis, which is well tolerated and has a number of important advantages over combined oral contraceptives. In addition, the available data indicate that patients are ready for possible irregular bleeding, which often occurs with the use of 2 mg of dienogest, since the drug reduces the painful manifestations of endometriosis.In clinical practice, important components of treatment management are counseling patients about expected side effects, evaluating the effectiveness and safety of each therapeutic approach, and following existing recommendations regarding the provision of individual care in accordance with the needs and wishes of each woman. Therefore, dienogest belongs to the standard of treatment of endometriosis, it is included in national and world clinical protocols as a drug of the first line of its treatment.

show abstract

“…Currently, according to the ESHRE guidelines, no biomarkers, measured in serum, urine or peritoneal fluid, are recommended for EMS diagnosis [13]. Nevertheless, the utility of various non-invasive diagnostic methods is still discussed in the literature, with the hope of developing non-invasive biomarker-based assays helping to detect EMS [28]. Thus, we assume that investigation of the Ucn1 role in EMS should aim at the same-not establishing it as a single independent diagnostic factor for usage in isolation but considering it as a one component of the complex diagnostic process.…”

Section: Ucn1 As a Potential Ems Biomarkermentioning

confidence: 99%

Possible Correlation between Urocortin 1 (Ucn1) and Immune Parameters in Patients with Endometriosis

Abramiuk

Frankowska

Kułak

et al. 2023

IJMS

View full text Add to dashboard Cite

The etiology of endometriosis (EMS) has not been clearly elucidated yet, and that is probably the reason why its diagnostic process is frequently long-lasting and inefficient. Nowadays, the non-invasive diagnostic methods of EMS are still being sought. Our study aimed to assess the serum and peritoneal fluid levels of urocortin 1 (Ucn1) in patients with EMS and healthy women. Moreover, considering the immune background of the disease, the association between Ucn1 and several immune parameters was studied in both groups. We found that the serum Ucn1 level was significantly upregulated in women with EMS compared to healthy patients. Moreover, higher serum Ucn1 levels tended to correspond with more advanced stages of the disease (p = 0.031). Receiver operating characteristic (ROC) analysis revealed that based on serum Ucn1 levels, it is possible to distinguish deep infiltrating endometriosis (DIE) from among other EMS types. Together, these results indicate Ucn1 as a possible promising biomarker of EMS: however, not in isolation, but rather to enhance the effectiveness of other diagnostic methods.

show abstract

Accuracy and utility of blood and urine biomarkers for the noninvasive diagnosis of endometriosis: a systematic literature review and meta-analysis

Cited by 8 publications

References 78 publications

A Comprehensive Review of the Diagnostic Landscape of Endometriosis: Assessing Tools, Uncovering Strengths, and Acknowledging Limitations

A Comprehensive Review of the Diagnostic Landscape of Endometriosis: Assessing Tools, Uncovering Strengths, and Acknowledging Limitations

The role of progestogens in the treatment of endometriosis

Possible Correlation between Urocortin 1 (Ucn1) and Immune Parameters in Patients with Endometriosis

Contact Info

Product

Resources

About